Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:
-Is isotretinoin making kids short?  
-Is Dupixent making them tall?  
-What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  
-What OTC supplement makes NBUVB work better for vitiligo?  
-What oral drug can you add to isotretinoin to make it work even better?  
-Does oral tranexamic acid increase the risk of blood clots when used in dermatology?
-How well does Opzelura work for hidradenitis suppurativa?
-Do Humira biosimilars work as well as Humira in hidradenitis suppurativa?
-What common statistical technique used by pharma is total BS?
-Which ingredient in 'keratin treatments" is causing kidney failure and kidney stones? 

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.

Here’s what we’re tackling:

• What hits harder on anxiety and depression—scarring or non-scarring alopecia?

• How tightly does AA severity track with psychological burden?

• How should you approach the mental health effects of AA?
  (Yes, you should ask. No, you shouldn’t be the one treating—here’s how to bridge patients to the right therapists.)

• And what do you do when a JAK Inhibitor isn’t giving you the results you hoped for?

This week, the Derms on Drugs are back with another literature speed-run—think 3D chess meets derm nerd nirvana. We’re answering questions you didn’t even know you had (and a few you wish you didn’t).

Here’s what we’re tackling:

• Do herbal supplements turn up dermatomyositis?

• Can biologics cut down on blood clots in HS?

• Wait… does Claritin supercharge isotretinoin?

• Is Sotyktu stirring up rosacea?

• How good is the new oral IL-23 inhibitor icotrokinra for psoriasis?

• Any fresh weapons against demodex?

• Anything new for those stubborn pemphigus oral lesions?

• What to do when your patient is resistant to multiple botulinum toxins?

• And—holy grail alert—can we actually prevent chemo-induced alopecia in breast cancer?

The Derms on Drugs are joined by Dr. Crystal Aguh from Johns Hopkins for an AMAZING discussion on central centrifugal scarring alopecia.  From uber practical, cheap, safe, effective treatment approaches to deep science on what is happening in this disease, listen this week and you'll be an expert - how to talk to these patients, the baseline treatments everybody should be on, when to get more aggressive, when to step therapy back - the whole enchilada.  We even throw in a little frontal fibrosing alopecia.  Quite honestly one of the best episodes we've ever done.  The Derms on Drugs learned new approaches to this disease and we promise, you will too!

Join us this week as the Derms on Drugs crew discusses the latest in the Dermatology literature.  Topics for this episode include:

- Cutaneous vasculitis of the skin (it’s a Chapel Hill thing)

- Ozempic face, butt, and body

- TAC injections for AA – what concentration do you use?

- Does the MERLIN study deserve its magical name?

- Are systemic JAK inhibitors the answer for vitiligo?

- And everyone’s favorite – Demodex mites!

You don't see a lot of kids with psoriasis, but when you do it can be a big challenge, especially if it's bad and they need a systemic.  The Derms on Drugs are coming to the rescue!  We'll have a special guest - Dr. Doug Kress (who was heavily involved in training all three of the Derms on Drugs) who has enormous experience treating pediatric psoriasis.  We'll get into all the stuff you really need to know:
-What systemic drugs are approved for psoriasis under the age of 18?
-What does the data say about which ones work the best?
-How good is Tremfya, the first IL-23 inhibitor approved in kids, and where will it fit?
-How is psoriasis in kids different from psoriasis in adults?
-What are the roles of the different topicals approved for psoriasis in kids?
-How do we think about therapy selection differently in kids vs adults?
-Do kids get psoriatic arthritis?
-What about shots vs pills in kids?
-How do you talk to parents about the different biologics for kids?
-How do you handle vaccines in kids who are psoriasis biologics?
-Do you ever use methotrexate in kids?

Brought to you by Scholars In Medicine

 The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like: 
 
-Do tattoos protect people against melanoma? 
-What cheap, easy topical works great for fissures in hand eczema? 
-Is Dupixent safe in pregnancy? 
-Are tinted sunscreens actually better than regular mineral sunscreens for melasma? 
-If an alopecia areata patient has failed two or three JAKs, is it worth trying another one? 
-What does the early data show for systemic JAK efficacy in vitiligo? 
-Is there anything better than triamcinolone to inject keloids with? 
-Does some crazy drug Patton found an article about work for hemodialysis associated itch? 
 
So, join us for another episode that'll make you better at what you do while you're having fun listening! 

Join the Derms on Drugs and Dr. Shanthi Narla as we dive into the world of obesity, GLP-1s and dermatology.  Whatever you think about all of these topics, we promise that your patients are hearing about them, reading about them and will be asking about them.  Specifically, we'll get into the latest data about how GLP-1s affect diseases like psoriasis, hidradenitis suppurativa and atopic dermatitis and we'll even touch on if dermatologists should be prescribing GLP-1s.  So, while there aren't any definite answers out there yet, tune in this week and you'll be ready when these hot topics come up!

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:
-When is the best time to start niacinamide for skin cancer prevention?
-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?
-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?
-What can do when for PLEVA that's not responding to the usual treatments?
-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?
-What can you do for patients with skin involvement of systemic mastocytosis?
-Are there patients who really have both atopic dermatitis AND psoriasis?
-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:
-When is the best time to start niacinamide for skin cancer prevention?
-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?
-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?
-What can do when for PLEVA that's not responding to the usual treatments?
-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?
-What can you do for patients with skin involvement of systemic mastocytosis?
-Are there patients who really have both atopic dermatitis AND psoriasis?
-Opzelura just got approved down to age 2 - how well does it work in that age range?